Biocon’s Kiran Mazumdar-Shaw Expects Early-Mover Bonanza In Biosimilars
Biocon Ltd. hopes to reap benefits of being an early mover in the global biosimilars market, according to its Chairperson and Managing Director Kiran Mazumdar-Shaw.
It will take a few years for many of the other domestic companies who have started investing in biosimilars now to catch up, Shaw told BloombergQuint in an interview. “The next few years can be bonanza years for Biocon.”
Biocon makes biosimilars or cheaper copies of biologic drugs that are manufactured from substances in living cells. The company manufactures and supplies advanced, life-saving biopharmaceuticals for diabetes, cancer and autoimmune conditions.
The European Commission and Therapeutic Goods Administration, the Australian regulator, recently gave marketing authorisation approval to insulin glargine Semglee biosimilar co-developed by Biocon and its global partner Mylan. The company plans to launch Semglee in the European Union in the second half of 2018, and late 2018 in Australia, according to a Morgan Stanley report.
This year we expect many more approvals...and biosimilars is certainly a business strategy that has worked well for us. We do not see aggressive competition for many years yet because its only now that many companies have started investing in biosimilars...Kiran Mazumdar-Shaw, CMD, Biocon
The company could get a revenue of $70-100 million from the Semglee biosimilar over the next couple of years, according to Morgan Stanley. “$70-100 million top line in two years is very much doable. I think the opportunity is much larger,” Mazumdar-Shaw said.
Watch the full interaction here:
Also Read: Biocon's Malaysian Plant Gets Six Observations From U.S. Drug Regulator
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.
